Literature DB >> 12000038

A genetic rat model of cholinergic hypersensitivity: implications for chemical intolerance, chronic fatigue, and asthma.

D H Overstreet1, V Djuric.   

Abstract

The fact that only some individuals exposed to environmental chemicals develop chemical intolerance raises the possibility that genetic factors could be contributing factors. The present communication summarizes evidence from a genetic animal model of cholinergic supersensitivity that suggests that an abnormal cholinergic system could be one predisposing genetic factor. The Flinders Sensitive Line (FSL) rats were established by selective breeding for increased responses to an organophosphate. It was subsequently found that these FSL rats were also more sensitive to direct-acting muscarinic agonists and had elevated muscarinic receptors compared to the selectively bred parallel group, the Flinders Resistant Line (FRL) rats, or randomly bred control rats. Increased sensitivity to cholinergic agents has also been observed in several human populations, including individuals suffering from chemical intolerance. Indeed, the FSL rats exhibit certain behavioral characteristics such as abnormal sleep, activity, and appetite that are similar to those reported in these human populations. In addition, the FSL rats have been reported to exhibit increased sensitivity to a variety of other chemical agents. Peripheral tissues, such as intestinal and airway smooth muscle, appear to be more sensitive to both cholinergic agonists and an antigen, ovalbumin. Hypothermia, a centrally mediated response, is more pronounced in the FSL rats after nicotine and alcohol, as well as agents that are selective for the dopaminergic and serotonergic systems. In some cases, the increased sensitivity has been detected in the absence of any changes in the receptors with which the drugs interact (dopamine receptors), while receptor changes have been seen in other cases (nicotine receptors). Therefore, there may be multiple mechanisms underlying the multiple chemical sensitivity-chemical intolerance of the FSL rats. An elucidation of these mechanisms may provide useful clues to those involved in chemical intolerance in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12000038     DOI: 10.1111/j.1749-6632.2001.tb05816.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration.

Authors:  Nigel S Bamford; Hui Zhang; John A Joyce; Christine A Scarlis; Whitney Hanan; Nan-Ping Wu; Véronique M André; Rachel Cohen; Carlos Cepeda; Michael S Levine; Erin Harleton; David Sulzer
Journal:  Neuron       Date:  2008-04-10       Impact factor: 17.173

2.  The contribution of Ca2+ signaling and Ca2+ sensitivity to the regulation of airway smooth muscle contraction is different in rats and mice.

Authors:  Yan Bai; Michael J Sanderson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-04-03       Impact factor: 5.464

3.  The reinforcement threshold and elasticity of demand for nicotine in an adolescent rat model of depression.

Authors:  John R Smethells; Danielle Burroughs; Amy Saykao; Paul R Pentel; Amir H Rezvani; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2020-12-03       Impact factor: 4.492

4.  Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study.

Authors:  Muriel Larauche; Agata Mulak; Yvette Taché
Journal:  J Neurogastroenterol Motil       Date:  2011-07-13       Impact factor: 4.924

5.  The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE).

Authors:  Derek F H Pheby; Diana Araja; Uldis Berkis; Elenka Brenna; John Cullinan; Jean-Dominique de Korwin; Lara Gitto; Dyfrig A Hughes; Rachael M Hunter; Dominic Trepel; Xia Wang-Steverding
Journal:  Medicina (Kaunas)       Date:  2021-04-16       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.